Bangladesh vs Togo: Average cost of multi drug-resistant tuberculosis treatment
Bangladesh
466 constant 2022 US$
in 2024
Togo
444 constant 2022 US$
in 2024
Bangladesh rank
81st
Togo rank
84th
Average cost of multi drug-resistant tuberculosis treatment over time
- Bangladesh
- Togo
How they compare
Bangladesh currently reports 466 constant 2022 US$ against 444 constant 2022 US$ in Togo, a difference of 22 constant 2022 US$.
The two have swapped places 2 times across 7 shared years of data; in 2018 it was Bangladesh ahead.
Bangladesh ranks 81st and Togo ranks 84th of 92 countries.
Across the 2 decades both report, Bangladesh averaged higher in 1 and Togo in 1.
Head to head by decade
| Decade | Bangladesh | Togo | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,436 constant 2022 US$ | 373 constant 2022 US$ | 1,064 constant 2022 US$ | Bangladesh |
| 2020s | 769 constant 2022 US$ | 874 constant 2022 US$ | 105 constant 2022 US$ | Togo |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Bangladesh or Togo?
- Bangladesh, at 466 constant 2022 US$ against 444 constant 2022 US$ in Togo as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Bangladesh and Togo?
- 22 constant 2022 US$, with Bangladesh ahead.
- How many years of comparable data are there for Bangladesh and Togo?
- 7 years are reported by both, from 2018 to 2024.
- How do Bangladesh and Togo rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Bangladesh ranks 81st and Togo ranks 84th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.